Kangkang Blood Pressure Submits IPO Prospectus: Kang Watch, the First CFDA-Certified Smart Blood Pressure Watch, Pioneers Medical-Grade Wearable Hypertension Management

At the Apple event held on September 13, Apple announced that the Apple Watch would feature an FDA-cleared electrocardiogram (ECG) function, enabling patients to perform real-time monitoring and share the results directly with healthcare professionals.

Notably, China’s smart wearable sector also warrants attention. The Kang Watch, a smart blood pressure monitor from Kangkang Blood Pressure, has obtained certification from the China Food and Drug Administration (CFDA). While the Apple Watch provides users with medical-grade ECG monitoring capabilities via a wrist-worn device, the Kang Watch addresses the need for medical-grade blood pressure monitoring in a similar form factor.

2018 can be regarded as the inaugural year for consumer-grade medical monitoring devices, with the Apple Watch and Kang Watch jointly leading medical-grade wearable devices into a new era.

Recently, Zeng Mingfa, founder and CEO of Kangkang Blood Pressure, showcased the Kang Watch—the first smart blood pressure monitor watch to receive certification from the China Food and Drug Administration (CFDA)—at the International Society of Hypertension Scientific Meeting (ISH 2018 Scientific Meeting), often referred to as the “Olympic Games” of the hypertension field.

Kang Kang Blood Pressure is recognized as the pioneer of “big data + hypertension chronic disease management” in China. It is a national high-tech enterprise, an undertaking unit for major special projects on chronic disease management under China’s 13th Five-Year Plan, and one of the Top 100 Big Data Application Scenarios at the 2018 “China Data Valley.” To date, it has established the world’s largest ambulatory blood pressure database.

Kang Kang Blood Pressure has continuously innovated in the field of smart wearable blood pressure devices. Since its establishment, it has successively launched innovative products such as the world’s first portable ambulatory blood pressure monitor and the world’s first cloud-based ambulatory blood pressure monitor, and has established in-depth collaborations with nearly 1,000 medical institutions.

Zeng Mingfa stated that Kang Watch integrates innovative technologies such as internationally leading wrist-mounted air pump measurement and customizable dynamic blood pressure monitoring. It is the world’s first smart blood pressure monitor watch to receive certification from the China Food and Drug Administration (CFDA), marking another major innovation by China’s intelligent wearable blood pressure technology in the field of international hypertension monitoring.

Both in appearance and functionality, the Kang Watch is far more than just a timepiece; its underlying “soft power” of “big data + blood pressure management” also deserves attention.

By leveraging Kang Watch, users can receive personalized diagnosis and treatment services for hypertension based on big blood pressure data. Kang Kang Blood Pressure boasts the industry’s most powerful capability in processing hypertension-related big data. As early as 2016, it partnered with the Chinese Hypertension League to establish the “National Remote Blood Pressure Monitoring and Big Data Processing Center,” and has since built the world’s largest ambulatory blood pressure sample database. This enables Kang Watch to incorporate Kang Kang Blood Pressure’s diagnostic models driven by big blood pressure data, delivering personalized and precise hypertension diagnosis and treatment plans for users.

Secondly, Kangkang Blood Pressure has developed the “AI-Based Cardiovascular Risk Assessment System” to predict disease incidence risk. Built upon the “Cardiovascular Risk Prediction Model” introduced by leading experts in the field, this system leverages artificial intelligence to efficiently calculate users’ cardiovascular disease risk scores, thereby shifting the focus of prevention to an earlier stage and encouraging users to adopt healthier lifestyles.

Furthermore, Kangkang Blood Pressure has partnered with a team of experts from top cardiovascular hospitals in China to provide remote interpretation services for ambulatory blood pressure monitoring (ABPM) reports, enabling every user to access expert remote interpretation services from Beijing’s Tier 3 Grade A hospitals without leaving home.